Izrael - hebrejščina - Ministry of Health

trupharm marketing 1985 ltd. - medicinal charcoal; rhubarb; sennae folium; sulfur purified - טבליה - sennae folium 105 mg; rhubarb 25 mg; sulfur purified 50 mg; medicinal charcoal 180 mg - medicinal charcoal, combinations - medicinal charcoal, combinations - mild laxative, anti-flatulant.

Izrael - hebrejščina - Ministry of Health

3m ישראל בע"מ - רופא שיניים - equipment, devices, materials + accessories used in dental medicine

Izrael - hebrejščina - Ministry of Health

ג'י אי מדיקל סיסטמס ישראל - צוות טכני - the system is general purpose product allowing for static, dynamic, whole body ,multigated cardiac tomographic and multigated tomographic nuclear medicine studies.

Izrael - hebrejščina - Ministry of Health

medici medical ltd, israel - factor viii (human) - אבקה להכנת תמיסה לזריקה - factor viii (human) 250 iu - coagulation factor viii - coagulation factor viii - is indicated for the prevention and control of bleeding in patients with moderate or severe factor viii deficiency due to classical hemophilia a .fanhdi is not effective in controlling the bleeding of patients with von willebrond's disease.

Izrael - hebrejščina - Ministry of Health

medici medical ltd, israel - factor viii (human) - אבקה להכנת תמיסה לזריקה - factor viii (human) 500 iu - coagulation factor viii - coagulation factor viii - is indicated for the prevention and control of bleeding in patients with moderate or severe factor viii deficiency due to classical hemophilia a . fanhdi is not effective in controlling the bleeding of patients with von willebrond's disease.

Izrael - hebrejščina - Ministry of Health

medici medical ltd, israel - factor viii (human) - אבקה להכנת תמיסה לזריקה - factor viii (human) 1000 iu - coagulation factor viii - coagulation factor viii - is indicated for the prevention and control of bleeding in patients with moderate or severe factor viii deficiency due to classical hemophilia a . fanhdi is not effective in controlling the bleeding of patients with von willebrond's disease.

Izrael - hebrejščina - Ministry of Health

medici medical ltd, israel - factor viii (human) - אבקה להכנת תמיסה לזריקה - factor viii (human) 1500 iu/dose - factor viii inhibitor bypassing activity - factor viii inhibitor bypassing activity - is indicated for the prevention and control of bleeding in patients with moderate or severe factor viii deficiency due to classical hemophilia a . fanhdi is not effective in controlling the bleeding of patients with von willebrond's disease.

Izrael - hebrejščina - Ministry of Health

medici medical ltd, israel - immunoglobulins, normal human - תמיסה לאינפוזיה - immunoglobulins, normal human 0.5 g / 10 ml - immunoglobulins, normal human, for intravascular adm. - immunoglobulins, normal human, for intravascular adm. - replacement therapy in: primary immunodeficiency syndromes such as:- congenital agammaglobulinaemia and hypogammaglobulinaemia- common variable immunodeficiency- severe combined immunodeficiency- wiskott aldrich syndromemyeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections.children with congenital aids and recurrent infections.immunomodulation :idiopathic thrombocytopenic purpura (itp), in children or adults at high risk of bleeding or prior to surgery to correct the platelet count.guillain barr? syndrome.kawasaki disease.allogeneic bone marrow transplantation

Izrael - hebrejščina - Ministry of Health

medici ltd - diphtheria toxoid 15 lf / 0.5 ml; filamentous haemogglutinin (fha) 5 mcg / 0.5 ml - suspension for injection - hemophilus influenzae b, combinations with pertussis and toxoids - primary vaccination of infants, at or above the age of two months and as a booster in children up to their 6th birthday against diphtheria, tetanus, pertussis and invasive haemophilus influenzae type b infection.

Izrael - hebrejščina - Ministry of Health

medici ltd - diphtheria toxoid 15 lf / 0.5 ml; filamentous haemogglutinin (fha) 20 mcg / 0.5 ml - suspension for injection - hemophilus influenzae b, combinations with pertussis and toxoids - primary vaccination of infants, at or above the age of two months and as a booster in children up to their 6th birthday against diphtheria, tetanus, pertussis, poliomyelitis and invasive haemophilus influenzae type b infections.